Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biological Specimen Banks | 3 | 2020 | 76 | 0.960 |
Why?
|
| Retinoblastoma | 3 | 2012 | 200 | 0.740 |
Why?
|
| Biomedical Research | 3 | 2020 | 806 | 0.590 |
Why?
|
| Retinal Neoplasms | 2 | 2012 | 144 | 0.460 |
Why?
|
| Oncolytic Viruses | 3 | 2013 | 204 | 0.440 |
Why?
|
| Picornaviridae | 2 | 2013 | 24 | 0.430 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2012 | 110 | 0.420 |
Why?
|
| Glycoproteins | 1 | 2012 | 747 | 0.330 |
Why?
|
| Retina | 1 | 2012 | 532 | 0.330 |
Why?
|
| Antigens, CD | 1 | 2012 | 1385 | 0.300 |
Why?
|
| Peptides | 1 | 2012 | 1479 | 0.280 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 2359 | 0.230 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2007 | 502 | 0.220 |
Why?
|
| Receptor, Notch4 | 1 | 2020 | 13 | 0.200 |
Why?
|
| Heart Septal Defects | 1 | 2020 | 51 | 0.190 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 2265 | 0.180 |
Why?
|
| Genetic Therapy | 1 | 2007 | 1616 | 0.180 |
Why?
|
| Research Personnel | 1 | 2020 | 156 | 0.170 |
Why?
|
| Oncolytic Virotherapy | 2 | 2013 | 280 | 0.170 |
Why?
|
| Hypoplastic Left Heart Syndrome | 2 | 2022 | 218 | 0.160 |
Why?
|
| Cytoskeletal Proteins | 1 | 2020 | 492 | 0.160 |
Why?
|
| Down Syndrome | 1 | 2020 | 226 | 0.160 |
Why?
|
| Heart Defects, Congenital | 2 | 2022 | 1697 | 0.150 |
Why?
|
| Repressor Proteins | 2 | 2016 | 1664 | 0.140 |
Why?
|
| Neoplasm Transplantation | 2 | 2011 | 1519 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2016 | 64 | 0.140 |
Why?
|
| Codon, Nonsense | 1 | 2016 | 164 | 0.140 |
Why?
|
| RNA Splicing Factors | 1 | 2016 | 153 | 0.130 |
Why?
|
| Quality Control | 1 | 2016 | 457 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2016 | 299 | 0.120 |
Why?
|
| Myocytes, Cardiac | 2 | 2022 | 764 | 0.120 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 1506 | 0.120 |
Why?
|
| Proteomics | 1 | 2020 | 1380 | 0.110 |
Why?
|
| Alternative Splicing | 1 | 2016 | 584 | 0.110 |
Why?
|
| PAX6 Transcription Factor | 1 | 2012 | 53 | 0.110 |
Why?
|
| AC133 Antigen | 1 | 2012 | 110 | 0.110 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 134 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 2045 | 0.100 |
Why?
|
| Eye Proteins | 1 | 2012 | 269 | 0.100 |
Why?
|
| Phenotype | 1 | 2022 | 6295 | 0.090 |
Why?
|
| Genomics | 1 | 2020 | 2738 | 0.090 |
Why?
|
| Brain Neoplasms | 3 | 2013 | 4849 | 0.090 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 238 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2013 | 7222 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2016 | 6150 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2012 | 5395 | 0.080 |
Why?
|
| Immunophenotyping | 1 | 2012 | 1681 | 0.080 |
Why?
|
| Stem Cells | 1 | 2014 | 1213 | 0.080 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2007 | 289 | 0.070 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 1143 | 0.070 |
Why?
|
| Hyaluronan Receptors | 1 | 2006 | 249 | 0.070 |
Why?
|
| Azetidines | 1 | 2006 | 87 | 0.070 |
Why?
|
| Flow Cytometry | 1 | 2012 | 3033 | 0.070 |
Why?
|
| Transduction, Genetic | 1 | 2006 | 475 | 0.070 |
Why?
|
| Hyaluronic Acid | 1 | 2006 | 168 | 0.070 |
Why?
|
| Medulloblastoma | 1 | 2010 | 540 | 0.070 |
Why?
|
| Mice | 6 | 2013 | 34495 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 548 | 0.060 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 4143 | 0.060 |
Why?
|
| Child | 3 | 2020 | 29154 | 0.060 |
Why?
|
| Trimethylsilyl Compounds | 1 | 2003 | 2 | 0.060 |
Why?
|
| Humans | 14 | 2022 | 261506 | 0.060 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2003 | 95 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2003 | 78 | 0.060 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2022 | 32 | 0.050 |
Why?
|
| Image Cytometry | 1 | 2022 | 47 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 1443 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5539 | 0.050 |
Why?
|
| Glioma | 1 | 2013 | 1963 | 0.050 |
Why?
|
| Steroids | 1 | 2003 | 356 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2006 | 1459 | 0.050 |
Why?
|
| Animals | 6 | 2013 | 59536 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2013 | 573 | 0.050 |
Why?
|
| Tetralogy of Fallot | 1 | 2022 | 149 | 0.050 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 192 | 0.050 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2022 | 244 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 3552 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 256 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 3981 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 429 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 338 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 470 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 167 | 0.040 |
Why?
|
| Monocytes | 1 | 2022 | 788 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2013 | 1869 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 778 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 5112 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2022 | 731 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 1972 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2020 | 9244 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8223 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 773 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2022 | 1682 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 699 | 0.030 |
Why?
|
| Amniotic Fluid | 1 | 2014 | 123 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2013 | 34 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2013 | 3821 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2014 | 626 | 0.030 |
Why?
|
| Troponin T | 1 | 2014 | 261 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 1471 | 0.030 |
Why?
|
| Cell Communication | 1 | 2014 | 509 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 6682 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2016 | 846 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 1082 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 2232 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1165 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 4109 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2007 | 32848 | 0.020 |
Why?
|
| Ezetimibe | 1 | 2006 | 101 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 13310 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 3536 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 3639 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2022 | 11965 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 4549 | 0.010 |
Why?
|
| Hydroxylation | 1 | 2003 | 65 | 0.010 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2003 | 42 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2014 | 4078 | 0.010 |
Why?
|
| Catalysis | 1 | 2003 | 250 | 0.010 |
Why?
|
| United States | 1 | 2020 | 15433 | 0.010 |
Why?
|
| Calibration | 1 | 2003 | 337 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2013 | 9180 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 1694 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2006 | 1129 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 5114 | 0.010 |
Why?
|
| Male | 2 | 2020 | 123000 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 4821 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 2927 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 4971 | 0.010 |
Why?
|
| Female | 2 | 2020 | 141928 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12221 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 7591 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 6942 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 6009 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 14551 | 0.010 |
Why?
|
| Mutation | 1 | 2006 | 15179 | 0.000 |
Why?
|